Combining drug-disease and economic modelling to inform drug development decisions

Drug Discovery Today

Volumn 6, Issue 22, 2001, Pages 1165-1170

  Poland, Bill ^a   Wada, Russell ^a  

^a PHARSIGHT CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DECISION MAKING; DRUG DEVELOPMENT; DRUG EFFICACY; ECONOMIC ASPECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MARKET; MODEL; PATIENT COMPLIANCE; PROBABILITY; REVIEW; SIMULATION; VIRUS LOAD;

EID: 0035889726     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)02014-1     Document Type: Review

References (9)

1. Simulation of clinical trials
2. Steering a course through the technology maze
3. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
4. Developing compliance instructions for drug labeling
5. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions
6. Medication compliance as a feature in drug development